Weiss Multi Strategy Advisers LLC Autolus Therapeutics PLC Transaction History

Weiss Multi Strategy Advisers LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $875 - $1,613	-429 Reduced 3.12%	13,324 $29,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $1,474 - $3,383	-723 Reduced 4.99%	13,753 $39,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $901 - $1,397	-256 Reduced 1.74%	14,476 $60,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $306 - $420	-60 Reduced 0.41%	14,732 $76,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $1,819 - $2,520	342 Added 2.37%	14,792 $97,000
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $2,466 - $4,107	516 Added 3.7%	14,450 $96,000
Q1 2021 May 14, 2021	SELL	$5.49 - $9.36 $25,210 - $42,981	-4,592 Reduced 24.79%	13,934 $80,000
Q4 2020 Feb 16, 2021	SELL	$8.13 - $12.79 $258,412 - $406,530	-31,785 Reduced 63.18%	18,526 $166,000
Q3 2020 Nov 16, 2020	BUY	$11.64 - $16.3 $6,495 - $9,095	558 Added 1.12%	50,311 $586,000
Q2 2020 Aug 14, 2020	BUY	$5.38 - $16.14 $8,608 - $25,824	1,600 Added 3.32%	49,753 $798,000
Q1 2020 May 15, 2020	SELL	$4.2 - $13.0 $7,757 - $24,011	-1,847 Reduced 3.69%	48,153 $288,000
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $302,000 - $625,000	20,000 Added 66.67%	50,000 $805,000
Q1 2019 May 15, 2019	BUY	$24.38 - $34.71 $73,140 - $104,130	3,000 Added 11.11%	30,000 $944,000
Q4 2018 Feb 14, 2019	SELL	$24.21 - $48.01 $146,301 - $290,124	-6,043 Reduced 18.29%	27,000 $887,000
Q3 2018 Nov 14, 2018	SELL	$20.86 - $33.33 $168,673 - $269,506	-8,086 Reduced 19.66%	33,043 $1.01 Million
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $1.03 Million - $1.14 Million	41,129 New	41,129 $1.1 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.